These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 31769393)

  • 21. Systems analysis-based assessment of post-treatment adverse events in lymphatic filariasis.
    Andersen BJ; Rosa BA; Kupritz J; Meite A; Serge T; Hertz MI; Curtis K; King CL; Mitreva M; Fischer PU; Weil GJ
    PLoS Negl Trop Dis; 2019 Sep; 13(9):e0007697. PubMed ID: 31557154
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy of single dose combinations of albendazole, ivermectin and diethylcarbamazine for the treatment of bancroftian filariasis.
    Ismail MM; Jayakody RL; Weil GJ; Nirmalan N; Jayasinghe KS; Abeyewickrema W; Rezvi Sheriff MH; Rajaratnam HN; Amarasekera N; de Silva DC; Michalski ML; Dissanaike AS
    Trans R Soc Trop Med Hyg; 1998; 92(1):94-7. PubMed ID: 9692166
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Residual microfilaraemia in rural pockets of South India after five rounds of DEC plus albendazole administration as part of the LF elimination campaign.
    Kalimuthu M; Sunish IP; Nagaraj J; Munirathinam A; Kumar VA; Arunachalam N; White GB; Tyagi BK
    J Vector Borne Dis; 2015 Jun; 52(2):182-4. PubMed ID: 26119554
    [No Abstract]   [Full Text] [Related]  

  • 24. Toward the elimination of lymphatic filariasis by 2020: treatment update and impact assessment for the endgame.
    Rebollo MP; Bockarie MJ
    Expert Rev Anti Infect Ther; 2013 Jul; 11(7):723-31. PubMed ID: 23879610
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A multicenter, community-based, mixed methods assessment of the acceptability of a triple drug regimen for elimination of lymphatic filariasis.
    Krentel A; Basker N; Beau de Rochars M; Bogus J; Dilliott D; Direny AN; Dubray C; Fischer PU; Ga AL; Goss CW; Hardy M; Howard C; Jambulingam P; King CL; Laman M; Lemoine JF; Mallya S; Robinson LJ; Samuela J; Schechtman KB; Steer AC; Supali T; Tavul L; Weil GJ
    PLoS Negl Trop Dis; 2021 Mar; 15(3):e0009002. PubMed ID: 33657090
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Towards elimination of lymphatic filariasis: social mobilization issues and challenges in mass drug administration with anti-filarial drugs in Tamil Nadu, South India.
    Nandha B; Krishnamoorthy K; Jambulingam P
    Health Educ Res; 2013 Aug; 28(4):591-8. PubMed ID: 23503571
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Report on active surveillance for adverse events following the use of drug co-administrations in the global programme to eliminate lymphatic filariasis.
    Wkly Epidemiol Rec; 2003 Sep; 78(36):315-7. PubMed ID: 14518107
    [No Abstract]   [Full Text] [Related]  

  • 28. The impact of repeated rounds of mass drug administration with diethylcarbamazine plus albendazole on bancroftian filariasis in Papua New Guinea.
    Weil GJ; Kastens W; Susapu M; Laney SJ; Williams SA; King CL; Kazura JW; Bockarie MJ
    PLoS Negl Trop Dis; 2008; 2(12):e344. PubMed ID: 19065257
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effectiveness of a triple-drug regimen for global elimination of lymphatic filariasis: a modelling study.
    Irvine MA; Stolk WA; Smith ME; Subramanian S; Singh BK; Weil GJ; Michael E; Hollingsworth TD
    Lancet Infect Dis; 2017 Apr; 17(4):451-458. PubMed ID: 28012943
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The safety of double- and triple-drug community mass drug administration for lymphatic filariasis: A multicenter, open-label, cluster-randomized study.
    Weil GJ; Bogus J; Christian M; Dubray C; Djuardi Y; Fischer PU; Goss CW; Hardy M; Jambulingam P; King CL; Kuttiat VS; Krishnamoorthy K; Laman M; Lemoine JF; O'Brian KK; Robinson LJ; Samuela J; Schechtman KB; Sircar A; Srividya A; Steer AC; Supali T; Subramanian S;
    PLoS Med; 2019 Jun; 16(6):e1002839. PubMed ID: 31233507
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety, tolerability, efficacy and plasma concentrations of diethylcarbamazine and albendazole co-administration in a field study in an area endemic for lymphatic filariasis in India.
    Kshirsagar NA; Gogtay NJ; Garg BS; Deshmukh PR; Rajgor DD; Kadam VS; Kirodian BG; Ingole NS; Mehendale AM; Fleckenstein L; Karbwang J; Lazdins-Helds JK
    Trans R Soc Trop Med Hyg; 2004 Apr; 98(4):205-17. PubMed ID: 15049459
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Fifteen years of programme implementation for the elimination of Lymphatic Filariasis in Ghana: Impact of MDA on immunoparasitological indicators.
    Biritwum NK; de Souza DK; Marfo B; Odoom S; Alomatu B; Asiedu O; Yeboah A; Hervie TE; Mensah EO; Yikpotey P; Koroma JB; Molyneux D; Bockarie MJ; Gyapong JO
    PLoS Negl Trop Dis; 2017 Mar; 11(3):e0005280. PubMed ID: 28333930
    [No Abstract]   [Full Text] [Related]  

  • 33. Coverage, compliance and some operational issues of mass drug administration during the programme to eliminate lymphatic filariasis in Orissa, India.
    Babu BV; Kar SK
    Trop Med Int Health; 2004 Jun; 9(6):702-9. PubMed ID: 15189460
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Individual Efficacy and Community Impact of Ivermectin, Diethylcarbamazine, and Albendazole Mass Drug Administration for Lymphatic Filariasis Control in Fiji: A Cluster Randomized Trial.
    Hardy M; Samuela J; Kama M; Tuicakau M; Romani L; Whitfeld MJ; King CL; Weil GJ; Grobler AC; Robinson LJ; Kaldor JM; Steer AC
    Clin Infect Dis; 2021 Sep; 73(6):994-1002. PubMed ID: 33728462
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Are Alternative Strategies Required to Accelerate the Global Elimination of Lymphatic Filariasis? Insights From Mathematical Models.
    Stolk WA; Prada JM; Smith ME; Kontoroupis P; de Vos AS; Touloupou P; Irvine MA; Brown P; Subramanian S; Kloek M; Michael E; Hollingsworth TD; de Vlas SJ
    Clin Infect Dis; 2018 Jun; 66(suppl_4):S260-S266. PubMed ID: 29860286
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An analysis of the safety of the single dose, two drug regimens used in programmes to eliminate lymphatic filariasis.
    Horton J; Witt C; Ottesen EA; Lazdins JK; Addiss DG; Awadzi K; Beach MJ; Belizario VY; Dunyo SK; Espinel M; Gyapong JO; Hossain M; Ismail MM; Jayakody RL; Lammie PJ; Makunde W; Richard-Lenoble D; Selve B; Shenoy RK; Simonsen PE; Wamae CN; Weerasooriya MV
    Parasitology; 2000; 121 Suppl():S147-60. PubMed ID: 11386686
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Country Reports on Practical Aspects of Conducting Large-Scale Community Studies of the Tolerability of Mass Drug Administration with Ivermectin/Diethylcarbamazine/Albendazole for Lymphatic Filariasis.
    Jambulingam P; Subramanian S; Krishnamoorthy K; Supali T; Fischer P; Dubray C; Fayette C; Lemoine JF; Laman M; King C; Samuela J; Hardy M; Weil GJ
    Am J Trop Med Hyg; 2022 May; 106(5_Suppl):18-25. PubMed ID: 35292582
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A triple-drug treatment regimen to accelerate elimination of lymphatic filariasis: From conception to delivery.
    Weil GJ; Jacobson JA; King JD
    Int Health; 2020 Dec; 13(Suppl 1):S60-S64. PubMed ID: 33349879
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Using knowledge, attitudes and practice (KAP) surveys on lymphatic filariasis to prepare a health promotion campaign for mass drug administration in Alor District, Indonesia.
    Krentel A; Fischer P; Manoempil P; Supali T; Servais G; Rückert P
    Trop Med Int Health; 2006 Nov; 11(11):1731-40. PubMed ID: 17054754
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Albendazole for mass drug administration to eliminate lymphatic filariasis.
    Sabesan S
    Lancet Infect Dis; 2006 Nov; 6(11):684-5. PubMed ID: 17067916
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.